JP2007509103A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509103A5
JP2007509103A5 JP2006536054A JP2006536054A JP2007509103A5 JP 2007509103 A5 JP2007509103 A5 JP 2007509103A5 JP 2006536054 A JP2006536054 A JP 2006536054A JP 2006536054 A JP2006536054 A JP 2006536054A JP 2007509103 A5 JP2007509103 A5 JP 2007509103A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
hydrogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509103A (ja
Filing date
Publication date
Priority claimed from GBGB0324654.3A external-priority patent/GB0324654D0/en
Application filed filed Critical
Publication of JP2007509103A publication Critical patent/JP2007509103A/ja
Publication of JP2007509103A5 publication Critical patent/JP2007509103A5/ja
Pending legal-status Critical Current

Links

JP2006536054A 2003-10-22 2004-10-20 医薬化合物 Pending JP2007509103A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324654.3A GB0324654D0 (en) 2003-10-22 2003-10-22 Medicinal compounds
PCT/EP2004/011952 WO2005040103A1 (en) 2003-10-22 2004-10-20 Medicinal compounds

Publications (2)

Publication Number Publication Date
JP2007509103A JP2007509103A (ja) 2007-04-12
JP2007509103A5 true JP2007509103A5 (enExample) 2007-10-11

Family

ID=29595615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536054A Pending JP2007509103A (ja) 2003-10-22 2004-10-20 医薬化合物

Country Status (8)

Country Link
US (1) US20090105309A1 (enExample)
EP (1) EP1675823B1 (enExample)
JP (1) JP2007509103A (enExample)
AT (1) ATE402141T1 (enExample)
DE (1) DE602004015316D1 (enExample)
ES (1) ES2309571T3 (enExample)
GB (1) GB0324654D0 (enExample)
WO (1) WO2005040103A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ[2.2.1]ヘプタ−7−イルアミン誘導体およびその使用
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
UY31905A (es) 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
MX2011007036A (es) 2008-12-30 2011-07-20 Pulmagen Therapeutics Inflammation Ltd Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
ZA824902B (en) * 1981-07-11 1983-04-27 Beecham Group Plc Secondary amines
EP0118489A1 (en) * 1982-08-27 1984-09-19 Beecham Group Plc Secondary arylethanolamines
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
ZA862665B (en) * 1985-04-16 1986-11-26 Hoffmann La Roche Phenethanolamine derivatives
EP0198412B1 (de) * 1985-04-16 1989-03-22 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Phenäthanolaminderivate
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5860645A (en) * 1995-10-20 1999-01-19 Canon Kabushiki Kaisha Sheet supplying apparatus
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
JP2005523920A (ja) * 2002-04-25 2005-08-11 グラクソ グループ リミテッド フェネタノールアミン誘導体

Similar Documents

Publication Publication Date Title
JP2007509103A5 (enExample)
JP2007509852A5 (enExample)
JP2006504766A5 (enExample)
JP2005511508A5 (enExample)
JP2006506373A5 (enExample)
RU2004106555A (ru) Производные фенэтаноламина для лечения респираторных заболеваний
JP2005533868A5 (enExample)
JP2005523920A5 (enExample)
JP2007514691A5 (enExample)
RU2238933C2 (ru) Аминобензофеноны как ингибиторы ил-1 бэта и tnf-альфа
RU2005111975A (ru) Производные фенэтаноламина для лечения респираторных заболеваний
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2004526720A5 (enExample)
TW201443043A (zh) 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US20030158176A1 (en) Quaternary ammonium compounds
JP2009084270A5 (enExample)
JP2004524308A5 (enExample)
JP2007502264A5 (enExample)
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
JP6218940B2 (ja) キニン系化合物、その光学異性体及びその製造方法と医薬用途
CN1615861A (zh) (1s,2s)-1-(4-羟基苯基)-2-(4-羟基-4-苯基哌啶-1-基)-1-丙醇甲磺酸盐三水合物
JP2007505931A5 (enExample)
JP2011521938A5 (enExample)
JP2007522162A5 (enExample)
JP2007515467A5 (enExample)